UNSPSC 51201576: Tofacitinib

Tofacitinib is an immunosuppressant (a medicine that reduces the activity of the immune system) that works by blocking the action of enzymes known as Janus kinases and used to treat rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis.

UNSPSC 51201576 Tofacitinib, a Commodity code, does not reflect the actual scope of state and local procurement activity tagged under it. The recent opportunities posted under this code span pharmaceutical services delivery, EMS medical supply distribution, forensic drug standards, opioid treatment settlement grants, and procurement networking events—none of which involve tofacitinib or pharmaceutical manufacturing. The code appears to serve as a catch-all placeholder for diverse pharmacy and medical supply procurement rather than a dedicated channel for this specific immunosuppressive medication.

The issuing bodies span county health systems, fire departments, medical centers, and forensic laboratories across Florida, Oregon, Texas, Wisconsin, Colorado, and Arizona. Dane County (Wisconsin) and Collier County (Florida) represent active users, with Dane County issuing a five-year RFP for comprehensive pharmaceutical services to a long-term care facility (response due October 22, 2026) emphasizing local-vendor preference and Collier County pursuing a single-source award to Pediatric Emergency Standards Inc. for EMS drug-dosage calculation software (protest deadline September 24, 2026). The City of Tucson Fire Department sought BLS/ALS pharmaceuticals and vending-machine services (June 2026), while West Texas Centers for Mental Health requested pharmacy services across 23 counties (August 2026). Geographic activity concentrates in Florida and Texas, with secondary activity in Wisconsin, Arizona, and Oregon. Formal pharmaceutical procurement solicitations remain sparse; most tagged opportunities involve adjacent services such as medical supply distribution networks, forensic reference materials, or opioid-settlement-funded treatment infrastructure rather than branded pharmaceuticals.